Bright Minds Biosciences (DRUG) Retained Earnings (2020 - 2026)

Bright Minds Biosciences has reported Retained Earnings for 7 years, with the latest figure at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 148.51% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.4 million (up 148.51% YoY), and the FY2025 full-year result was $3.9 million, up 32.95% from the prior year.
• Retained Earnings for Q1 2026 stood at $5.4 million, up from $4.8 million in the prior quarter.
• The five-year high for Retained Earnings was $5.4 million in Q1 2026, with the low at -$23.5 million in Q3 2023.
• Historically, Retained Earnings has averaged $1.2 million across 5 years, with a median of $2.2 million in 2023.
• Annual changes were most pronounced in 2023 — Retained Earnings plunged 1337.79% — and 2026, when it soared 148.51%.
• Bright Minds Biosciences' Retained Earnings stood at $2.2 million in 2022, then advanced by 13.9% to $2.5 million in 2023, then retreated by 10.57% to $2.2 million in 2024, then soared by 114.49% to $4.8 million in 2025, then rose by 12.46% to $5.4 million in 2026.
• The last three Retained Earnings figures came in at $5.4 million (Q1 2026), $4.8 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.